{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:51Z","timestamp":1790651991394,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["BI-2107-38160"],"award-info":[{"award-number":["BI-2107-38160"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40263-025-01191-7","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:53:25Z","timestamp":1748544805000},"page":"693-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3877-6763","authenticated-orcid":false,"given":"Giovanni","family":"Novi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3823-4000","authenticated-orcid":false,"given":"Francesca","family":"Bovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sciolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Minetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Garelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Luca","family":"Spiezia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schiavetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Malentacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Mataluni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rolando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Solla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cellerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Uccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"1","key":"1191_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"1191_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1191_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306.","journal-title":"Lancet Neurol"},{"key":"1191_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102538","volume":"46","author":"SA Brod","year":"2020","unstructured":"Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord. 2020;46: 102538.","journal-title":"Mult Scler Relat Disord."},{"key":"1191_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201260","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, Fitzgerald KC, Levy M, Pardo CA, et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology. 2022. https:\/\/doi.org\/10.1212\/WNL.0000000000201260.","journal-title":"Neurology"},{"issue":"3","key":"1191_CR6","doi-asserted-by":"publisher","first-page":"1130971","DOI":"10.3389\/fopht.2023.1130971","volume":"16","author":"P Sudhakar","year":"2023","unstructured":"Sudhakar P, Abusamra K, Thandampallayam M, Kini A. New advancements in the management of neuromyelitis optica spectrum disease: literature review. Front Ophthalmol. 2023;16(3):1130971.","journal-title":"Front Ophthalmol."},{"issue":"1","key":"1191_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, H\u00e4u\u00dfler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"key":"1191_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101430","volume":"36","author":"G Novi","year":"2019","unstructured":"Novi G, Bovis F, Capobianco M, Frau J, Mataluni G, Curti E, et al. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Multiple Scler Relat Disord. 2019;36: 101430.","journal-title":"Multiple Scler Relat Disord."},{"issue":"2","key":"1191_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"11","key":"1191_CR10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412.","journal-title":"Arch Neurol"},{"issue":"2","key":"1191_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1191_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"1191_CR13","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0. [cited 2025 Apr 13]. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"9","key":"1191_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","volume":"263","author":"P Annovazzi","year":"2016","unstructured":"Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, et al. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol. 2016;263(9):1727\u201335.","journal-title":"J Neurol"},{"issue":"8","key":"1191_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1177\/13524585231172145","volume":"29","author":"BG Weinshenker","year":"2023","unstructured":"Weinshenker BG, Wingerchuk DM, Green AJ, Bennett JL, Kim HJ, Pittock SJ, et al. Attack adjudication in neuromyelitis optica spectrum disorder: substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. Multiple Scler. 2023;29(8):945\u201355.","journal-title":"Multiple Scler"},{"key":"1191_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105093","volume":"80","author":"N Molazadeh","year":"2023","unstructured":"Molazadeh N, Akaishi T, Bose G, Nishiyama S, Chitnis T, Levy M. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis. Mult Scler Relat Disord. 2023;80: 105093.","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"1191_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209940","volume":"103","author":"P Siriratnam","year":"2024","unstructured":"Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, et al. Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG\u2013positive NMOSD. Neurology. 2024;103(12): e209940.","journal-title":"Neurology"},{"issue":"10","key":"1191_CR18","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1177\/13524585231187120","volume":"29","author":"E Carnero Contentti","year":"2023","unstructured":"Carnero Contentti E, Lopez PA, Tkachuk V, Vrech C, Zarate MA, Correale J, et al. Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting. Mult Scler. 2023;29(10):1240\u20139.","journal-title":"Mult Scler"},{"issue":"5","key":"1191_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001179","volume":"9","author":"SH Kim","year":"2022","unstructured":"Kim SH, Park NY, Kim KH, Hyun JW, Kim HJ. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience. Neurol Neuroimmunol Neuroinflamm. 2022;9(5): e1179.","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01191-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:46:49Z","timestamp":1749808009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01191-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01191-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for conducting this study. F.B. received the 2022 Biostatistic\/Informatics Junior Faculty Award (grant code BI-2107-38160) awarded by the National MS Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"G.N. received speaker honoraria from Alexion, Roche, and Novartis; J.F. reports a relationship with Biogen, Bristol, Novartis, Genzyme, Merck, Teva, and Alexion that includes: board membership, consulting or advisory, and speaking and lecture fees; M.V.\u00a0received compensation for travel grants or speaking activities from Biogen, Merck Serono, Roche, BMS Cellgene, Janssen, and Novartis; E.S.e.\u00a0has received speaker honoraria and support for attending scientific meetings from Alexion. He serves as an editorial board member for BMC Neurology and Frontiers in Neurology and is a member of the Medical Advisory Board of the MOG project; R.F. received honoraria for advisory boards and consulting from Bristol MS, Roche, Merck, and Novartis; C.Z. reports that the Ente Ospedaliero Cantonale (employer) received compensation for speaking activities, consulting fees, or research grants from Almirall, Biogen Idec, Bristol Meyer Squibb, Lundbeck, Merck, Novartis, Sanofi, Teva Pharma, and Roche; E.S.i. reports a relationship with Almirall, Biogen, Genzyme, Novartis, and Teva that includes: board membership and travel reimbursement; L.B. received honoraria for speaking from Novartis, Roche, and Horizon and for traveling from Sanofi-Genzyme, Merck-Serono, Novartis, Horizon, and Roche; she acted as an Advisory Board Member of Sanofi-Genzyme, Novartis, and Merck-Serono, and she is involved as principal investigator in clinical trials for Roche and Merck-Serono; M.L. has received honoraria from Biogen, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Almirall, and Bayer for consulting services, speaking, and\/or travel support; S.B. reports a relationship with Novartis, Merck-Serono, Alexion, BMS, Biogen, Roche, Janssen-Cilag, and Horizon that includes: speaking and lecture fees and travel reimbursement; I.S. reports a relationship with Roche, Biogen, Horizon, Novartis, Hoya, Hippocrates Research, D.M.G Italia, Eyepharma, and DreamsLab that includes: consulting or advising; M.Ma. received fees from Novartis and Biogen Idec for speaking in scientific meetings; E.C. has received honoraria for consultancy or speaking from Bayer Biogen, Novartis, Sanofi, Merck, TEVA, Roche, Bristol, Janssen, and Alexion; M.G. received honoraria for the participation in advisory boards from Roche and UCB; P.S. has received speaker honoraria from Bayer and Zambon; M.C. received personal compensations from Novartis, Genzyme, and Teva and consulting fees from Zambon; A.d.S. received compensation for speaking and consulting by Biogen, Novartis, Roche, Sanofi, Alexion, and Sandoz and reimbursement by Merck, Biogen, Genzyme, and Roche for attending conferences; A.U. received grants (for his institution) from FISM, Biogen, Roche, Alexion, and Merck Serono; participated on a Data Safety Monitoring Board or Advisory Board (at his institution) for BD, Biogen, Iqvia, Sanofi, Roche, Alexion, and Bristol Myers Squibb; M.P.S. reports a relationship with Biogen Idec, Merck Serono, Teva, Genzyme, Roche, Novartis, GeNeuro, and Medday that includes: consulting or advising.\u00a0M.P.S. is also an Editorial Board Member of CNS Drugs. M.P.S. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. F.B., C.S., M.M.i., F.N., G.G., A.B., P.G., A.L.S., G.S., L.G., A.F., G.M., A.R., G.A., and R.L. have no relevant financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data are available upon reasonable request from the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study was approved by the Ethics Committee of IRCCS Ospedale Policlinico San Martino, Genova, protocol 067REG2017.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided written consent to participate in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"G.N.\u2014drafting\/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; FB\u2014drafting\/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: graphic presentation. C.S., J.F., M.M., F.N., M.V., G.G., A.B., P.G., A.L.S., R.F., G.S., L.G., E.S., L.B., M.L., S.B., I.S., M.M., E.C., A.F., G.M., A.R., P.S., M.C., G.A., R.L., A.d.S., and A.U.\u2014drafting\/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; E.S., M.G., M.P.S.\u2014drafting\/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. All authors read and approved the final submitted paper and agree to be accountable for this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}